The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Optimizing treatment for geriatric patients with CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses optimizing treatment for older patients with chronic lymphocytic leukemia (CLL). She highlights that several targeted therapies are now suitable for this demographic and that clinical trials increasingly include less fit older populations. She references a study indicating that geriatric assessments during venetoclax and obinutuzumab treatment showed improved geriatric functioning, suggesting that the treatment itself may reduce the need for pre-treatment optimization. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
